Patents by Inventor Maureen D. O'Connor

Maureen D. O'Connor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12084510
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGER) having an EGER binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: September 10, 2024
    Assignees: Gilead Sciences, Inc., National Research Council of Canada
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
  • Publication number: 20240254195
    Abstract: There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGF? superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and/or low red blood cell levels (such as anemia).
    Type: Application
    Filed: December 22, 2023
    Publication date: August 1, 2024
    Inventors: Maureen D. O'CONNOR-MCCOURT, Vannakambadi K. GANESH, Gilles TREMBLAY, Gauthier SCHANG
  • Publication number: 20240101641
    Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
    Type: Application
    Filed: August 29, 2023
    Publication date: March 28, 2024
    Applicant: National Research Council of Canada
    Inventors: Anne E.G. LENFERINK, John C. Zwaagstra, Traian Sulea, Maureen D. O'Connor-McCourt
  • Patent number: 11866481
    Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 9, 2024
    Assignee: National Research Council of Canada
    Inventors: Anne E. G. Lenferink, John C. Zwaagstra, Traian Sulea, Maureen D. O'Connor-McCourt
  • Publication number: 20220204587
    Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-?) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
    Type: Application
    Filed: March 1, 2018
    Publication date: June 30, 2022
    Inventors: Anne E.G. LENFERINK, John C. ZWAAGSTRA, Traian SULEA, Maureen D. O'CONNOR-MCCOURT
  • Publication number: 20220169702
    Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
    Type: Application
    Filed: November 10, 2021
    Publication date: June 2, 2022
    Applicant: National Research Council of Canada
    Inventors: John C. Zwaagstra, Traian Sulea, Maria L. Jaramillo, Maureen D. O'Connor, Anne E.G. Lenferink
  • Publication number: 20210238302
    Abstract: The present invention provides a set of Carbonic Anhydrase-IX monoclonal antibodies (CA-IX mAbs) that bind with high affinity to cell-surface expressed hCA-IX and has enzyme inhibiting characteristics. These mAbs have the potential to become the next biologics for the treatment of renal and possibly other types of cancer.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 5, 2021
    Inventors: Anne E. G. LENFERINK, Maureen D. O'CONNOR
  • Publication number: 20200325243
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Application
    Filed: February 21, 2020
    Publication date: October 15, 2020
    Inventors: Ilia Alexandre TIKHOMIROV, Maria L. JARAMILLO, Maureen D. O'CONNOR-MCCOURT, Traian SULEA, Renald GILBERT, Bruno GAILLET, Jason BAARDSNES, Myriam BANVILLE, Suzanne GROTHE
  • Publication number: 20200231652
    Abstract: The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-beta) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
    Type: Application
    Filed: August 31, 2016
    Publication date: July 23, 2020
    Applicant: National Research Council of Canada
    Inventors: John C. Zwaagstra, Traian Sulea, Maria Jaramillo, Maureen D. O'Connor, Anne E.G. Lenferink
  • Patent number: 10570211
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: February 25, 2020
    Assignees: GILEAD SCIENCES, INC., NATIONAL RESEARCH COUNCIL OF CANADA
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
  • Patent number: 10487153
    Abstract: The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: November 26, 2019
    Assignee: National Research Council of Canada
    Inventors: Anne E. G. Lenferink, Maureen D. O'Connor, Anne Marcil, Yves Durocher
  • Publication number: 20190194349
    Abstract: An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3). For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID NO. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.
    Type: Application
    Filed: December 31, 2018
    Publication date: June 27, 2019
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville
  • Patent number: 10208129
    Abstract: An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59 YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3) For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID No. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: February 19, 2019
    Assignee: National Research Council of Canada
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes
  • Publication number: 20180186893
    Abstract: The present invention relates to isolated or purified antibodies or fragments thereof specific for Carbohydrate Anhydrase IX (CA-IX) and their use as therapeutic tools. Specifically, the present invention is directed to high-affinity Carbohydrate Anhydrase IX-specific antibodies and fragments thereof and their use as antibody-drug conjugates. Compositions for use in therapy as well as therapeutic methods are also described.
    Type: Application
    Filed: June 10, 2016
    Publication date: July 5, 2018
    Applicant: National Research Council of Canada
    Inventors: Anne E.G. Lenferink, Maureen D. O'Connor, Anne Marcil, Yves Durocher
  • Patent number: 8987417
    Abstract: The present invention addresses limitations of prior art receptor-based traps through a methodology called the clamp/click/cleave (CCC) approach. Two fusion proteins each comprising a binding domain fused to a coiled-coil are non-covalently dimerized through the coiled-coil (clamp), and the dimer so formed is stabilized by a covalent disulphide bond (click) between cysteine residues located on the fusion proteins between the binding domains and coiled-coils. Once the disulphide bond has formed, the coiled-coils are subsequently removed (cleave) by cleaving the fusions proteins at cleavage sites located between the cysteine residues and the coiled-coils to provide the covalently dimerized bivalent binding agent of the present invention. Such binding agents are useful in the treatment and diagnosis of disease states characterized by production and/or overexpression of a ligand to which the binding domains bind.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: March 24, 2015
    Assignee: National Research Council of Canada
    Inventors: John C. Zwaagstra, Maureen D. O'Connor-McCourt, Traian Sulea, Catherine Collins, Myriam Banville, Maria L. Jaramillo
  • Patent number: 8734760
    Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: May 27, 2014
    Assignee: National Research Coucil of Canada
    Inventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes
  • Patent number: 8658135
    Abstract: The invention provides hetero-multivalent ligand binging agents (traps) for members of the TGF-? superfamily, as well as methods for making and using such constructs. In an embodiment of the invention there is provided a hetero-multivalent binding agent with affinity for a member of the TGF-? superfamily. The agent comprises the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where bd1, bd2, bd3 and bd4 are polypeptide binding domains having an affinity for different sites on the same member or for different members of the TGF-? superfamily; at least two of bd1, bd2, bd3, and bd4 are different from each other.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: February 25, 2014
    Assignee: National Research Council of Canada
    Inventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes, Catherine Collins
  • Patent number: 8629240
    Abstract: Peptides are disclosed that are useful for molecular imaging or diagnosis of a disease state, such as cancer, in which clusterin is upregulated.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: January 14, 2014
    Assignee: National Research Council of Canada
    Inventors: Rana Filfil, Dmitri Tolkatchev, Feng Ni, Maureen D. O'Connor-McCourt, Anne E. G. Lenferink
  • Publication number: 20130295086
    Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 7, 2013
    Applicants: NATIONAL RESEARCH COUNCIL OF CANADA, YM BIOSCIENCES INC.
    Inventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
  • Patent number: 8574548
    Abstract: The invention provides multivalent ligand binding agents (traps) for members of the TGF-? superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-? superfamily, the agent having the general structure I: (<bd1>-linker1)k-[{<bd1>-linker2-<bd2>-linker3f-}n-(<bd3>)m-(linker4-<bd4>)d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-? superfamily; and, linkers are unstructured polypeptide sequences.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: November 5, 2013
    Assignee: National Research Council of Canada
    Inventors: Maureen D. O'Connor-McCourt, Traian Sulea, John C. Zwaagstra, Jason Baardsnes